tert-butyl N-[2-[4-[5-cyano-2-[4-[2-(2-ethylimidazol-1-yl)ethyl]anilino]pyrimidin-4-yl]phenyl]propan-2-yl]carbamate | 314268-09-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: tert-butyl N-[2-[4-[5-cyano-2-[4-[2-(2-ethylimidazol-1-yl)ethyl]anilino]pyrimidin-4-yl]phenyl]propan-2-yl]carbamate
• CAS: 314268-09-2
• 化学式: C₃₂H₃₇N₇O₂
• 分子量: 551.691
• InChiKey: NUHCWXYMAHTXJK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  41
• 可旋转键数：
  11
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  118
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tert-butyl N-[2-[4-[5-cyano-2-[4-[2-(2-ethylimidazol-1-yl)ethyl]anilino]pyrimidin-4-yl]phenyl]propan-2-yl]carbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以95%的产率得到4-[4-(1-Amino-1-methylethyl)phenyl]-5-cyano-N-{4-[2-(2-ethylimidazol-1-yl)ethyl]phenyl}pyrimidine-2-amine
  参考文献：
  名称：

  4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: Synthesis and biological evaluation

  摘要：

  A novel series of 4-aryl-5-cyano-2-aminopyrimidines were synthesized and found to have potent VEGF-R2 kinase inhibitory activity. Structure-activity relationships were investigated and compound 14a was shown to be efficacious in a mouse model of corneal neovascularization. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.021
• 作为产物：
  描述：

  1,1-dimethylethyl[1-[4-(5-isoxazolyl)phenyl]-1-methylethyl]carbamate 在 sodium hydroxide 、 碳酸氢钠 、 三乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl N-[2-[4-[5-cyano-2-[4-[2-(2-ethylimidazol-1-yl)ethyl]anilino]pyrimidin-4-yl]phenyl]propan-2-yl]carbamate
  参考文献：
  名称：

  4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: Synthesis and biological evaluation

  摘要：

  A novel series of 4-aryl-5-cyano-2-aminopyrimidines were synthesized and found to have potent VEGF-R2 kinase inhibitory activity. Structure-activity relationships were investigated and compound 14a was shown to be efficacious in a mouse model of corneal neovascularization. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.04.021

文献信息

• 5-cyano-2-aminopyrimidine derivatives
  申请人：——

  公开号：US20020147339A1

  公开（公告）日：2002-10-10

  Pyrimidines of formula (1) are described 1 wherein Ar is an optionally substituted aromatic or heteroaromatic group; R 1 is a hydrogen atom or a straight or branched chain alkyl group; R 2 is a —X 1 —R 3 group where X 1 is a direct bond or a linker atom or group, and R 3 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states associated with angiogenesis.

  公式（1）中描述了嘧啶类化合物，其中Ar是可选择取代的芳香或杂芳基团；R1是氢原子或直链或支链烷基基团；R2是一个—X1—R3基团，其中X1是直接键或连接原子或基团，而R3是可选择取代的脂肪、环脂肪、杂原子脂肪、杂环脂肪、芳香或杂芳基团；以及它们的盐、溶剂合物、水合物和N-氧化物。这些化合物是选择性的KDR激酶和/或FGFr激酶抑制剂，并可用于预防和治疗与血管生成相关的疾病状态。
• [EN] 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES<br/>[FR] DERIVES DE 5-CYANO-2-AMINOPYRIMIDINE
  申请人：CELLTECH CHIROSCIENCE LTD

  公开号：WO2000078731A1

  公开（公告）日：2000-12-28

  Pyrimidines of formula (1) are described wherein Ar is an optionally substituted aromatic or heteroaromatic group; R1 is a hydrogen atom or a straight or branched chain alkyl group; R2 is a -X1-R3 group where X1 is a direct bond or a linker atom or group, and R3 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states associated with angiogenesis.

  描述了式（1）的嘧啶类化合物，其中Ar是可选择的取代芳香族或杂环芳香族基团；R1是氢原子或直链或支链烷基；R2是-X1-R3基团，其中X1是直接键或连接原子或基团，R3是可选择的取代脂肪族、环状脂肪族、杂原子脂肪族、杂环脂肪族、芳香族或杂环芳香族基团；以及其盐、溶剂合物、水合物和N-氧化物。这些化合物是选择性的KDR激酶和/或FGFr激酶抑制剂，可用于预防和治疗与血管生成相关的疾病状态。
• 5-Cyano-2-aminopyrimidine derivatives
  申请人：Celltech R&D Limtied

  公开号：US20040180914A1

  公开（公告）日：2004-09-16

  Pyrimidines of formula (1) are described 1 wherein Ar is an optionally substituted aromatic or heteroaromatic group; R 1 is a hydrogen atom or a straight or branched chain alkyl group; R 2 is a —X 1 —R 3 group where X 1 is a direct bond or a linker atom or group, and R 3 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective KDR Kinase and/or FGFr Kinase inhibitors and are of use in the prophylaxis and treatment of disease states assoicated with angiogenesis.

  描述了化学式（1）的嘧啶类化合物，其中Ar是可选取代的芳香族或杂环芳香族基团；R1是氢原子或直链或支链烷基；R2是—X1—R3基团，其中X1是直接键或连接原子或基团，R3是可选取代的脂肪族、环状脂肪族、杂原子脂肪族、杂环脂肪族、芳香族或杂环芳香族基团；以及其盐、溶剂合物、水合物和N-氧化物。这些化合物是选择性KDR激酶和/或FGFr激酶抑制剂，可用于预防和治疗与血管生成相关的疾病状态。
• 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES
  申请人：Celltech R&D Limited

  公开号：EP1187816A1

  公开（公告）日：2002-03-20
• US6579983B1
  申请人：——

  公开号：US6579983B1

  公开（公告）日：2003-06-17